GENOME EDITING OF COGNITION RELATED GENES IN ANIMALS
First Claim
Patent Images
1. A genetically modified animal comprising at least one edited chromosomal sequence encoding a cognition-related protein.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding proteins that are associated with cognitive disorders. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences associated with cognitive disorders.
127 Citations
36 Claims
- 1. A genetically modified animal comprising at least one edited chromosomal sequence encoding a cognition-related protein.
- 15. A non-human embryo, the embryo comprising at least one RNA molecule encoding a zinc finger nuclease that recognizes a chromosomal sequence encoding a cognition-related protein, and, optionally, at least one donor polynucleotide comprising a sequence encoding a cognition-related protein.
- 19. A genetically modified cell, the cell comprising at least one edited chromosomal sequence encoding a cognition-related protein.
-
27. A method for assessing the effect of an agent in an animal, the method comprising administering the agent to a genetically modified animal comprising at least one edited chromosomal sequence encoding a cognition-related protein, and comparing a selected parameter obtained from the genetically modified animal to the selected parameter obtained from a wild-type animal administered the same agent, wherein the selected parameter is chosen from:
-
a) rate of elimination of the agent or its metabolite(s); b) circulatory levels of the agent or its metabolite(s); c) bioavailability of the agent or its metabolite(s); d) rate of metabolism of the agent or its metabolite(s); e) rate of clearance of the agent or its metabolite(s); f) toxicity of the agent or its metabolite(s); and g) efficacy of the agent or its metabolite(s). - View Dependent Claims (28, 29, 30, 31)
-
-
32. A method for assessing the therapeutic potential of an agent as a treatment for a cognitive disorder, the method comprising administering the agent to a genetically modified animal, wherein the genetically modified animal comprises at least one edited chromosomal sequence encoding a cognition-related protein, and comparing a selected parameter obtained from the genetically modified animal to the selected parameter obtained from a wild-type animal with no exposure to the same agent, wherein the selected parameter is chosen from:
-
a) spontaneous behaviors; b) performance during behavioral testing; c) physiological anomalies; d) abnormalities in tissues or cells; e) biochemical function; and f) molecular structures. - View Dependent Claims (33, 34, 35, 36)
-
Specification